Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Bitcoin roars back from Chinese-regulation spurred swoon September 19, 2017 Ransomware threat: Cyber chaos may grow as world logs in on Monday May 15, 2017 igus helps automate German red worm factory August 23, 2018